"MARKET SPIRAL PRICING OF CANCER DRUGS"
Senior oncologist, Hagop Kantarjian, and I show that very high prices for cancer & specialty drugs are not due to high costs of research, nor to added clinical value. Companies are simply spiraling up prices already 2-3 times greater than other capitalist countries allow, because we allow them to.
High co-pays hurt patients and impede good clinical care.
This exploitation of serious ill patients and taxpayers is ethically troubling and must stop.